MetaCap

Cerenome (CNSY) vs SkyAI (SKYA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

SkyAI (SKYA) has outperformed Cerenome (CNSY) over the past year, losing 23.0% versus a loss of 95.2%. SkyAI is the larger company by market cap ($7.8 million vs $6.2 million), about 1.3 times the size. Cerenome converts more of its revenue into profit, with a net margin of -429.4% versus -138400.0%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CNSY-95.24%SKYA-22.97%
+53%-25%-103%
Nov 21, 20251 yearNov 20, 2026
CNSY-99.82%SKYA-99.98%
+5%-50%-105%
Apr 11, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CNSY versus SKYA key metrics
MetricCNSYSKYA
Share price$0.6301$2.18
Market cap$6.16M$7.82M
1-day change-10.29%-45.50%
YTD return-95.06%+7.39%
1-year return-95.24%-22.97%
5-year return-99.89%—
P/E ratio (TTM)—2.83
EPS (TTM)$-3.50$0.77
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$5.21M$204.12K
Revenue growth (YoY)-10.49%—
Net income (latest FY)$-22.39M$-282.50M
Gross margin—-202.49%
Operating margin-293.46%-132145.49%
Net margin-429.43%-138400.02%
52-week high$19.00$4.39
52-week low$0.43$0.91
Distance from 52-week high-96.68%-50.34%
Analyst consensusstrong_buy—
Avg. price target upside+4304.06%—
Average volume804.18K1.74M
Shares outstanding9.78M3.59M
Employees2830
SectorHealth CareHealth Care
IndustryMedical/Dental InstrumentsMedical/Dental Instruments

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • SKYA has outperformed CNSY by 72.3 percentage points over the past year.
  • Cerenome is more profitable, keeping -429.4 cents of every revenue dollar as net income versus -138400.0 cents for SkyAI.

About Cerenome

CNSY stock →

Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.

Health Care · Medical/Dental Instruments · 28 employees

About SkyAI

SKYA stock →

SkyAI, Inc., a financial technology company with a Solana digital asset treasury that is building an agentic finance platform. It combines stablecoin rails with AI to deliver financial access, education, and actionable intelligence to the underbanked users in Asia, Latin America, and Africa.

Health Care · Medical/Dental Instruments · 30 employees

CNSY vs SKYA FAQ

Which is bigger, Cerenome or SkyAI?

SkyAI (SKYA) is larger, with a market capitalization of $7.82M compared with $6.16M for Cerenome (CNSY).

Which stock has performed better over the past year, CNSY or SKYA?

SKYA returned -22.97% over the past 12 months, compared with -95.24% for CNSY (price return, excluding dividends). Past performance does not predict future results.

Are Cerenome and SkyAI in the same industry?

Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.

More comparisons